Guidance on the provision of information pertaining to clinical trials for patients and the general public, 3rd ed.
Drug Evaluation Committee
November 2023
The Drug Evaluation Committee of the Japan Pharmaceutical Manufacturers Association (hereafter referred to as "JPMA") formulated the "Guidelines for the Provision of Information for the Recruitment of Subjects for Clinical Trials <Revised Version>" (hereafter referred to as "Previous Guidelines") in November 2008, which was provided to member companies and has been in operation.
Subsequently, in response to the requirements for the provision of clinical trial information by pharmaceutical companies in "Handling of Information Provision for Clinical Trials" (January 24, 2023, Pharmaceutical Affairs Bureau, AIST No. 0124-1), the Pharmaceutical Manufacturers Association of Japan (PMAJ) established "Guidelines for Information Provision for Clinical Trials" in June 2023 to ensure transparency in the implementation of clinical trials and to improve patient access to clinical trials. In June 2023, the Pharmaceutical Manufacturers Association of Japan (PMAJ) issued the "Basic Policy on the Handling of Information Provision for Clinical Trials" (hereinafter referred to as the "Basic Policy") to ensure transparency in the conduct of clinical trials and improve patient access.
This time, we have reviewed the old guidelines and prepared new guidelines for the provision of information on clinical trials conducted by pharmaceutical companies, etc., as "Guidelines for the Provision of Information on Clinical Trials for Patients and the General Public, Third Edition" (hereinafter referred to as "the Guidelines"). Since this guideline includes information on clinical trials provided at the time of subject recruitment, the "Basic Concept" and the "Old Guideline" will be abolished with the issuance of this guideline.